Get the Stockscreener App
73.74
21.38%
13.01
Metsera Inc stock is traded at $73.74, with a volume of 8.15M.
It is up +21.38% in the last 24 hours and up +42.03% over the past month.
Metsera Inc is a clinical-stage biotechnology company developing next-generation injectable and oral nutrient-stimulated hormone (NuSH) analog peptides to treat obesity, overweight, and related conditions. The Company has developed and is implementing proprietary methods and platform technologies to advance a broad, scalable, and combinable portfolio of injectable and oral NuSH analog peptides with the potential to address not only the limitations of approved therapies but also many of the anticipated limitations of next-generation therapies in development. The Company uses its proprietary MINT peptide library of NuSH analog peptides alongside its Half-life Augmentation by Lipid Optimization half-life extending platform.
See More
Previous Close:
$60.73
Open:
$68.9
24h Volume:
8.15M
Relative Volume:
3.51
Market Cap:
$7.74B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+40.62%
1M Performance:
+42.03%
6M Performance:
+187.39%
1Y Performance:
+0.00%
1-Day Range:
$68.00
$74.00
1-Week Range:
$51.92
$74.00
52-Week Range:
$12.30
$74.00
Metsera Inc Stock (MTSR) Company Profile
Name
Metsera Inc
Sector
Industry
Phone
(212) 784-6595
Address
3 WORLD TRADE CENTER, NEW YORK
Compare MTSR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MTSR
Metsera Inc
|
73.72 | 6.39B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.16 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
629.15 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
424.92 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
837.09 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
184.56 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Metsera Inc Stock (MTSR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-09-25 | Initiated | Leerink Partners | Outperform |
| Jun-20-25 | Initiated | Wells Fargo | Overweight |
| Feb-25-25 | Initiated | BofA Securities | Buy |
| Feb-25-25 | Initiated | Evercore ISI | Outperform |
| Feb-25-25 | Initiated | Guggenheim | Buy |
View All
Metsera Inc Stock (MTSR) Latest News
Novo Nordisk Outbids Pfizer In $10 Billion Metsera Takeover Battle - Finimize
Novo Nordisk Is Still Beating Pfizer in Battle Over Metsera - Barron's
Palantir, Hertz, Metsera, Uber, DraftKings: Stocks Making The Biggest Moves Today - Stocktwits
Teneo Refs Bidding War for Metsera - O'Dwyer's PR
Novo, Pfizer Boost Metsera Bids in Obesity Startup Battle - MarketScreener
Pfizer Metsera Lawsuit - Buffalo News
M&A News: Novo Nordisk Stock (NVO) Slides after Increasing Its Metsera Offer to $10B - TipRanks
Pfizer, Novo Nordisk escalate bidding war for obesity drug developer Metsera By Reuters - Investing.com
Delaware judge does not see current need for court in Metsera bidding war between Pfizer and Novo - WTAQ
Novo Nordisk hikes Metsera bid to up to $10B in competition with rival Pfizer - WFMZ.com
Novo Nordisk tops Pfizer in bidding war for obesity startup Metsera - Proactive financial news
Pfizer, Novo Nordisk escalate bidding war for obesity drug developer Metsera - Reuters
Metsera’s Shares Spike Amid Acquisition Proposals from Novo Nordisk and Pfizer - StocksToTrade
Takeover Saga for Obesity Drugmaker Metsera Heats Up - Bloomberg
Metsera rises after Novo Nordisk and Pfizer sweeten bids - TradingView
Novo Nordisk (NVO) Raises Bid to Acquire Metsera, Outbidding Pfi - GuruFocus
Delaware court won't rule on Pfizer/Novo battle for Metsera today - Seeking Alpha
Delaware judge does not see current need for court in Metsera bidding war between Pfizer and Novo By Reuters - Investing.com
Novo Sweetens Its Bid For Metsera, Pledging Up To $10 Billion - Investor's Business Daily
Pfizer Fields Novo’s $10B Curveball, With Bourla Promising To Fight for Metsera - BioSpace
Novo Nordisk, Pfizer sweeten bid for Metsera as bidding war heats up - Yahoo Finance
Metsera Considers Novo Nordisk’s Superior Acquisition Proposal - TipRanks
Novo Nordisk’s (NVO) $9B Metsera Bid Sparks Showdown with Archrival Pfizer (PFE) - TipRanks
Metsera receives amended ‘superior’ proposal from Novo Nordisk - TipRanks
Metsera saga continues, with upped bids from Novo and Pfizer - The Pharma Letter
Pfizer, Novo Nordisk Escalate Bidding War for Weight-Loss Drug Startup - The Wall Street Journal
Pfizer & Novo boost Metsera bids, Hertz stock skyrockets - Yahoo Finance
Metsera Inc Declares Novo Nordisk Proposal Superior - TradingView
Metsera Gets 'Superior' Acquisition Bid From Novo Nordisk, Challenging Pfizer Merger - MarketScreener
Pfizer, Novo Boost Bids for Obesity Drugmaker Metsera in Takeover Saga - Bloomberg.com
Novo Nordisk Hikes Metsera Bid to up to $10B in Competition With Rival Pfizer - U.S. News & World Report
Novo Nordisk (NVO) Extends Enhanced Acquisition Offer for Metser - GuruFocus
/C O R R E C T I O N -- Metsera, Inc./ - Placera.se
Novo Nordisk CEO faces baptism of fire amid board shakeup, Pfizer fight - Reuters
NVO's Acquisition Offer Values Metsera at $10B - GuruFocus
Novo, Pfizer's bidding war heats up with supercharged offers for Metsera - Fierce Biotech
Pfizer, Novo Nordisk improve offers for Metsera as bidding war escalates - Capital Brief
Metsera, Inc. Stock Soars Amid Acquisition Drama - TipRanks
Metsera Receives Amended Proposal from Novo Nordisk - citybiz
Novo Nordisk (NVO) Offers Enhanced Proposal to Metsera - GuruFocus
Novo Nordisk and Pfizer sweeten bids for Metsera - Axios
Novo Ups Ante In Metsera Buyout Drama With $10B Offer, Beating Pfizer’s New Bid - BioSpace
Metsera stock soars as Novo Nordisk, Pfizer sweeten bids in takeover battle - Investing.com
Novo Nordisk Sweetens Offer for Metsera - The Wall Street Journal
Pfizer Boosts Profit View While Chasing Obesity Startup Metsera - Bloomberg
Bidding war between Pfizer, Novo Nordisk for obesity startup Metsera escalates - statnews.com
Novo Nordisk submits updated proposal to acquire Metsera - MarketScreener
Metsera Gets Revised Bids From Pfizer, Novo Nordisk: Here’s Why It Matters - Stocktwits
Metsera says Novo Nordisk’s new up to $10 billion bid for obesity drugmaker is ‘superior’ to revised Pfizer offer - CNBC
Novo Nordisk submits updated proposal to acquire Metsera, Inc. - The Manila Times
Both Novo Nordisk and Pfizer have adjusted their bids for Metsera. - MarketScreener
Metsera Inc Stock (MTSR) Financials Data
There is no financial data for Metsera Inc (MTSR). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.25%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):